AntibodyPlus: next generation antibody-based biologics

Judy Lieberman MD PhD

Antibody mediated SARS CoV2 Infection of Monocytes and Macrophages Activates Inflammation

The Lieberman laboratory studies cytotoxic T lymphocytes and NK and their role in immune protection from infection and cancer, focusing on the molecular pathways used to kill both mammalian cells and microbes (bacteria and parasites). Her lab was the first to describe CD8 T cell exhaustion in humans, which is the basis for current checkpoint blockade therapies for treating cancer. They also identified the mechanism behind inflammatory death (pyroptosis) triggered by innate immune recognition of pathogens and danger signals and the role of pyroptosis in infection and cancer. Recent work has identified important roles for pyroptosis in SARS-CoV-2, Yersinia, and Group A streptococcal infection. They recently found that monocytes are infected by SARS-CoV-2 in an ACE-2-independent pathway that depends on recognition of antibody-coated virions by CD16 and once infected trigger a potent inflammatory response that contributes to severe COVID-19 infection.

Her laboratory has also been in the forefront of developing RNAi-based therapeutics and using RNAi for genome-wide screening. They were the first to show that siRNAs could be used to treat disease in vivo and to develop cell-targeted RNAs that knockdown gene expression in vivo in immune cells and cancer. Cell-specific gene knockdown was based on antibody or aptamer-targeted siRNAs.

Dr. Lieberman is a member of the American Academy of Arts and Sciences, the National Academy of Sciences and the National Academy of Medicine.

Mitchell Ho, Ph.D.

Advances in Solid Tumor CART Cell Therapy

Afternoon session Moderator

Dr. Ho is a Senior Investigator, Deputy Chief of the Laboratory of Molecular Biology, and Director of the Antibody Engineering Program at the National Cancer Institute (NCI), National Institutes of Health (NIH). He is the Chair of the Department of Biochemistry for the FAES Graduate School at the NIH. He also serves as the Editor-in-Chief for Antibody Therapeutics (Oxford University Press).
Dr. Ho’s research has been focused on the development of new therapeutic paradigms for several difficult to treat cancers including liver cancer, rare cancers such as mesothelioma, and childhood cancers such as neuroblastoma. A major focus of Dr. Ho’s research is on the structure and function of glypicans (e.g., GPC3, GPC2) and establishing them as new cancer-specific targets. This area of research ranges from investigation of the mechanisms by which glypicans regulate Wnt, Yap and other signaling pathways to the development of new antibody engineering technologies that lead to effective cancer therapeutics. In line with the antibody technology development, his lab has constructed shark and camel single-domain antibody phage libraries for therapeutic antibody discovery. Some of his laboratory research has direct clinical application. Clinical trials using the CAR-T cells created in his lab are ongoing for treating liver cancer and other cancers.
Dr. Ho received his Ph.D. from the University of Illinois at Urbana-Champaign. He completed a postdoctoral fellowship with Ira Pastan at the NIH/NCI. He was elected to the Board of Directors for the Antibody Society, the Board of Directors for the Chinese Antibody Society, and the Board of Directors for the Foundation for Advanced Education in the Sciences (FAES). He received Asian & Pacific Islander American Organization (APAO) Scientific Achievement Award, NIH Deputy Director for Intramural Research (DDIR) Innovation Award, NIH Merit Award, NCI Director's Award and NCI Director’s Innovation Award.

Paul Parren

Bispecific and avidity engineered antibodies in biotherapeutic drug design

Prof. Paul W.H.I. Parren is dedicated to translating antibody biology and immunotherapy knowledge into innovative therapeutics and technologies. He holds a PhD in molecular immunology from the University of Amsterdam (1992). Prof. Parren was an Associate Professor at The Scripps Research Institute in La Jolla, California. From 2002-2017, he led research and preclinical development at Genmab where he developed antibodies incorporated in seven FDA/EMA approved therapeutics to date. He is an inventor of ofatumumab (Arzerra, 2009; KESIMPTA, 2020), daratumumab (DARZALEX, 2015), teprotumumab (Tepezza, 2020), amivantamab (RYBREVANT, 2021), tisotumab vedotin (Tivdak, 2021) and two clinically translated technologies to generate bispecific (DuoBody) and effector-function enhanced (HexaBody) antibodies. He has a strong publication record with >230 scientific publications (>34,500 citations; h factor of 99; Google Scholar Jul. 1, 2022) and 150 granted patents in US and EU). He is a tenured Professor of Molecular Immunology at the Leiden University Medical Center in Leiden. In 2018, he joined LAVA Therapeutics, a biotechnology company that discovers and develops bispecific gamma-delta T cell engagers from its Gammabody platform to transform cancer therapy, as its Executive Vice President and Head of R&D. He provides drug development, patent and investment advice as an independent consultant from his company Sparring Bioconsult. Finally, he is the chair of the Board of Directors for The Antibody Society, an international non-profit trade organization that stimulates knowledge dissemination and represents individuals and organizations involved in antibody research and development.

Jingsong Wang, Ph.D.

Building Next Gen Biologics Leveraging Industry Leading Technology Platforms

Dr. Jingsong Wang is the Founder, Chairman of the Board of Directors and CEO of Harbour BioMed (HBM, HKEX: 02142). Before establishing HBM, Dr. Wang served as the Head of China Research and Development Center and the Founding Head of Translational Medicine for Asia Pacific at Sanofi. Dr. Wang joined Sanofi from Bristol-Myers Squibb, where he served multiple roles with increasing responsibilities, including Director of Discovery Medicine and Clinical Pharmacology and Global Program Lead for multiple pre-clinical and clinical assets. Prior to BMS, Dr. Wang was at Wyeth (now part of Pfizer) where he served as Associate Director, and later as the Head for Translational Medicine in Inflammation and Rheumatology, Women's Health and Musculoskeletal Diseases.

Dr. Wang completed his Clinical Rheumatology Fellowship and subsequently was an Attending Rheumatologist and faculty member at Brigham and Women's Hospital and Harvard Medical School. Dr. Wang received his PhD in Molecular Pharmacology from China Pharmaceutical University and has also completed a Molecular Immunology Research Fellowship in the lab of Dr. Laurie Glimcher at the Harvard School of Public Health.

Dr. Wang currently is an Adjunct Assistant Professor of Medicine at the University of Pennsylvania. He has served on the Research Grant Review Committee, National Natural Science Foundation of China, and as a scientific grant reviewer for the Medical Research Council, National Institute for Health Research, National Health Service of the United Kingdom. Dr. Wang has published dozens of papers on various academic journals and is the author and co-author of numerous books in the field of translational medicine, inflammation and autoimmune diseases.

Shirley Liu, PhD

Integrated Genomics and AI Approach for IO Target and Drug Discovery

Dr. Xiaole Shirley Liu co-founded GV20 Therapeutics in 2016 and became the CEO of GV20 in 2022. She was a Professor of Biostatistics and Computational Biology at Dana-Farber Cancer Institute and Harvard T.H. Chan School of Public Health and co-director of the Center for Functional Cancer Epigenetics at Dana-Farber Cancer Institute. Her computational biology work refined our understanding of hormone receptor therapies, epigenetic inhibitors, gamma-secretase inhibitors, receptor tyrosine kinase inhibitors, and immune checkpoint inhibitors in different cancers. Dr. Liu is a highly cited researcher with a prodigious publication record that includes more than 200 papers published by her group, many in high-profile journals and highly cited. Shirley received the Sloan Research Fellowship (2008), has been a Breast Cancer Research Foundation Investigator (2017) and became a Fellow of ISCB (2019). In addition, she was recognized with the Benjamin Franklin Award for Open Access in the Life Sciences and the ISCB Innovator Award in 2020. Recently, she was selected by the American Institute for Medical and Biological Engineering (AIMBE) to its 2022 College of Fellows.

Zhiqiang An

Academic drug discovery challenges and opportunities

Dr. Zhiqiang An is Professor of Molecular Medicine, the Robert A. Welch
Distinguished University Chair in Chemistry, and Director of the Texas Therapeutics
Institute at the University of Texas Health Science Center at Houston. His laboratory
focuses on antibody drug resistance mechanisms, biomarkers for therapeutic
antibodies, and antibody drug discovery targeting human diseases. During the last five
years, more than 10 novel antibody drug leads discovered in his laboratory were
licensed to seven biotech companies, and five have advanced to clinical trials.
Previously, he served as Chief Scientific Officer at Epitomics, Inc. and was Director
of Biologics Research at Merck Research Laboratories. He has authored over 200
journal articles and two books including the award-winning book “Therapeutic
Monoclonal Antibodies: from Bench to Clinic”. He is an elected fellow of Society for
Industrial Microbiology and Biotechnology (SIMB), the American Academy of
Microbiology (ASM), American Association for the Advancement of Science
(AAAS), and the National Academy of Inventors (NAI). Dr. An received his Ph.D.
degree from the University of Kentucky and his postdoctoral training at the University
of Wisconsin-Madison.

Kenneth LaMontagne

Combining gamma delta T cells with Bispecific Antibodies to fight cancer

Ken has recently joined In8Bio as a SVP Business Development since June 2022. Dr. LaMontagne brings 22 years of Oncology experience including R&D, Translational Sciences, Commercialization, Business Development & Licensing. Prior to joining IN8Bio, Dr. LaMontagne held senior roles at both large pharma, including Novartis, J&J and BMS, and small biotechnology companies, including Legend and Artisan Bio.
Dr. LaMontagne has done over 50+ due diligences in Oncology covering diverse therapeutic modalities and included small molecules, biologics, cell & gene therapies, spanning pre-clinical to post-marketing assets. Dr. LaMontagne contributed to the first FDA-approved CAR-T therapy, KYMRIAH, while leading the business insights team in the Cell & Gene Therapies Unit at Novartis. After completing his Ph.D. graduate studies at Cold Spring Harbor Laboratory, Dr. LaMontagne was a post-doctoral fellow in the laboratory of the late Dr. Judah Folkman at Harvard Medical School. Dr. LaMontagne has an Executive MBA in Strategy from Rutgers Business School and is currently in the Executive General Management Program in the Wharton School at the University of Pennsylvania.

John Lambert

ANTIBODY DRUG CONJUGATES Decades of Study Successful Product Developments and a Resurgence of Interest

Dr. Lambert graduated from Christ’s College, University of Cambridge (England, UK), with a degree in Natural Sciences in 1972. He then earned a Ph.D. in Biochemistry from the University of Cambridge in 1976, working on the structure of glycolytic enzymes under the supervision of Professor Richard N. Perham.

Dr Lambert’s postdoctoral training was at the University of California, Davis (1976-1980), working on ribosome structure in the laboratory of Dr Robert R. Traut, and at the University of Glasgow, Scotland, UK (1980-1982), working on the arom multienzyme complex in the laboratory of Dr John R. Coggins.

In 1982, Dr. Lambert joined the Dana-Farber Cancer Institute, Harvard Medical School, as the second scientist recruited to work on the ImmunoGen-funded programs to develop
antibody-drug conjugates (ADCs) and immunotoxins as anti-cancer therapeutics.

Dr. Lambert joined ImmunoGen in 1987 when the company established independent research laboratories in Cambridge, Massachusetts. After working in a variety of roles at the company, Dr. Lambert served as Chief Scientific Officer from 2008 until 2015. In 2016, he became a Distinguished Research Fellow at the company until his retirement at the end of 2017. He served on the Executive Committee of the company as Executive Vice President, Research, from 2008 until 2016.

During Dr Lambert’s tenure in leadership roles at ImmunoGen, scientists at the company invented the ADC technology that ultimately resulted in the Genentech/Roche drug, Kadcyla® (approved in 2013 for treating HER2+ breast cancer), as well as numerous other ADCs taken into clinical development. One of these is ImmunoGen’s mirvetuximab soravtansine, an ADC currently under regulatory review (BLA) by FDA for the treatment of folate receptor alpha-positive, platinum-resistant ovarian cancer.

Since 2018, to date, Dr Lambert consults with and/or advises a number of Biopharma and Pharma companies and some VC firms on ADC technologies.

Dr Lambert is the author/co-author of over 125 peer-reviewed scientific publications. In 2016, Dr Lambert was elected as a Fellow of the American Institute for Medical and Biological Engineering (AIMBE). In 2018, he was appointed to an Honorary Professorship at Queen’s University Belfast, Northern Ireland, UK.

Dr Lambert is a resident of Cambridge, Massachusetts, USA.

Chen Ni Chin

Engineered IgM antibodies as potential therapeutics

Yue Liu, PhD, MBA

Machine learning guided generation of antibody therapeutics

Yue has over 10 years’ experience in drug discovery and has spent majority of her time in the research and development sectors in both large pharma and biotech companies. In her current role as a team lead and project lead, she excels at applying interdisciplinary knowledge of antibody R&D and lab automation to characterize antibody at scale, and in integrating the wet lab and dry lab capabilities to build machine learning technology platform and pipeline programs. Yue completed her Ph.D. in Pharmacology from University of Florida and MBA from U Mass Amherst.

Hao Cheng, PhD

A Novel Single B cell Based Platform for Monoclonal Antibody Discovery

TBD

Shouye Wang, Ph.D.

Openning remarks

Zhidan Tu, Ph.D.

Announcements of Chinese Antibody Society

Bo Liu, Ph.D

Yearly Review of Chinese Antibody Society

Zhinan Xia, Ph.D

Morning session Moderator

Registration and Breakfast

Organizer, TBD, The Chinese Antibody Society

Coming Soon!

Openning remarks

Shouye Wang, Ph.D., Board Director, Chinese Antibody Society

Coming Soon!

Announcements of Chinese Antibody Society

Zhidan Tu, Ph.D., Presedent, Chinese Antibody Society

Coming Soon!

Yearly Review of Chinese Antibody Society

Bo Liu, Ph.D, President-elect, Chinese Antibody Society

Coming Soon!

Morning session Moderator

Zhinan Xia, Ph.D, CSO, DynamiCure Biotechnology

Coming Soon!

Antibody mediated SARS CoV2 Infection of Monocytes and Macrophages Activates Inflammation

Judy Lieberman MD PhD, Endowed Chair, Harvard Medical School

Coming Soon!

Advances in Solid Tumor CART Cell Therapy

Mitchell Ho, Ph.D., Senior Investigator, NIH

Coming Soon!

Coffee break

Organizer, TBD, The Chinese Antibody Society

Coming Soon!

Building Next Gen Biologics Leveraging Industry Leading Technology Platforms

Jingsong Wang, Ph.D., CEO, Harbour BioMed

Coming Soon!

Integrated Genomics and AI Approach for IO Target and Drug Discovery

Shirley Liu, PhD, CEO, GV20

Coming Soon!

Combining gamma delta T cells with Bispecific Antibodies to fight cancer

Kenneth LaMontagne, SVP, IN8bio

Coming Soon!

Lunch

Organizer, TBD, The Chinese Antibody Society

Coming Soon!

Afternoon session Moderator

Mitchell Ho, Ph.D., Senior Investigator, NIH

Coming Soon!

Academic drug discovery challenges and opportunities

Zhiqiang An, Professor of Molecular Medicine, University of Texas Health Science Center at Houston

Coming Soon!

Bispecific and avidity engineered antibodies in biotherapeutic drug design

Paul Parren, EVP and Head of R&D, Lava Therapeutics

Coming Soon!

Machine learning guided generation of antibody therapeutics

Yue Liu, PhD, MBA, Associate Director, Generate Biomedicines

Coming Soon!

Coffee break

Organizer, TBD, The Chinese Antibody Society

Coming Soon!

A Novel Single B cell Based Platform for Monoclonal Antibody Discovery

Hao Cheng, PhD, CSO, Yurogen

Coming Soon!

Engineered IgM antibodies as potential therapeutics

Chen Ni Chin, Senior Director, IGM Biosciences

Coming Soon!

ANTIBODY DRUG CONJUGATES Decades of Study Successful Product Developments and a Resurgence of Interest

John Lambert, Consultant/Scientific Advisor, Queen’s University Belfast

Coming Soon!

Exhibit

Organizer, TBD, The Chinese Antibody Society

Coming Soon!

Dinner

Organizer, TBD, The Chinese Antibody Society

Coming Soon!